Merck & Co., Inc. (MRK) – Keytruda, still the top driver

in , , on May 2, 2023

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Merck & Co., Inc. (MRK) (Q4FY22)


MRK sales were $59.3bn an increase of 22% in FY22 attributable in part to higher sales in the virology franchise driven by Lagevrio. Also contributing to revenue growth were higher sales in the oncology franchise largely due to strong growth of Keytruda and increased alliance revenue from Lenvima.


– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

CrispIdea Coverage

No of Pages: 33

To download the previous quarter’s equity report click here

Follow our LinkedIn page for more updates

Release Information

  • Price


  • Released

    May 2, 2023

  • Last Updated

    May 2, 2023